Becton Dickinson

BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.

The assay, which received premarket approval last year, detects 14 high-risk HPV types and individually identifies and reports HPV genotypes 16, 18, and 45.

For fiscal 2020, BD provided guidance for revenue growth in the 4 to 4.5 percent range, or 5 to 5.5 percent on a currency-neutral basis.

The test is the latest in a series of CE-IVD-marked assays the company has launched for use on Becton Dickinson's PCR-based BD Max platform.

10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.

In response to BD's patent suit, 10x alleged BD's single-cell products infringe its own patents. 10x also asked the judge to dismiss BD's lawsuit.

The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.

Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.

Revenues were in line with Wall Street estimates, and revenue growth represented strength across all three of the firm's business segments.